VistaGen fails phase 2 depression trial, sparking stock rout

purple brain
A phase 2 failure of AV-101 in major depressive disorder drove VistaGen’s share price down below $1. (Raman Oza/Pixabay)

A phase 2 trial of VistaGen Therapeutics’ AV-101 in major depressive disorder has missed its primary endpoint, sending shares in the nanocap biotech down 64% premarket. VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Expectations for the phase 2 were dampened in May when an investigator-sponsored trial of AV-101 suggested the NMDA receptor glycine site antagonist is ineffective in depression as a monotherapy.  VistaGen pointed to differences between the designs of the two trials to caution against reading too much into the first failure, but ultimately the top-line takeaways from the studies were similar.

In the latest readout, VistaGen found AV-101 was no better than placebo at improving scores on the MADRS-10 depression scale, causing the study to miss its primary endpoint. VistaGen is yet to share data from the 199-subject study, but the qualitative impression is of an unequivocal failure. 

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

"The rigorous conduct of the study makes us confident that AV-101, at the concentrations used, was not effective,” Massachusetts General Hospital’s Maurizio Fava, the study’s principal investigator, said in a statement.

VistaGen is yet to give up on AV-101, though. CEO Shawn Singh pointed to the possibility that either AV-101 may have failed to cross the blood-brain barrier in sufficient quantities or that too little of the active metabolite accrued in the target tissue to argue the drug may have a future. If those reasons explain the failure, VistaGen thinks combining AV-101 with anion transport inhibitor probenecid may help. 

Singh and his colleagues plan to keep reviewing preclinical and clinical data on AV-101 in a handful of indications into 2020 before deciding whether to run further studies. The lack of psychotomimetic side effects or serious adverse events in the phase 2 means tolerability is unlikely to be a barrier to further development.

VistaGen wants to push ahead with other programs while figuring out what to do with AV-101. Nasal spray PH94B is set to enter phase 3 in social anxiety disorder while PH10 is moving into phase 2 in major depressive disorder. 

Whether VistaGen can bankroll all of its planned activities is another question. VistaGen ended September with $4.1 million in cash and cash equivalents. With the phase 2 failure driving VistaGen’s share price down below $1, the biotech’s ability to raise cash is constrained. 

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.